Reading CATX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CATX free→Reading CATX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CATX free→QuarterlyIQ Insights · CATX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after…
Results of Operations and Financial Condition. On May 4, 2026, Perspective Therapeutics, Inc. (the “Company”) posted to its website a presentation (the “Presentation”) containing slides presented at an analyst event hosted by the Company on that date and certain other slides regarding the Company’s clinical programs and manufacturing technologies and infrastructure. The Presentation contains certain estimated and projected financial information, including the Company’s estimated cash, cash eq…
The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after…
Entry into a Material Definitive Agreement. On February 2, 2026, Perspective Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Piper Sandler & Co. and UBS Securities LLC, as representatives of the underwriters named therein (the “Underwriters”), in connection with its previously announced underwritten offering (the “Offering”) of 39,576,088 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common S…
Results of Operations and Financial Condition. On February 2, 2026, Perspective Therapeutics, Inc. (the "Company") updated its corporate presentation (the "Presentation"). The Presentation contains certain estimated and projected financial information, including the Company’s estimated cash, cash equivalents and short-term investments as of December 31, 2025. The estimated and projected financial information included in the Presentation is preliminary and has not been audited, reviewed or com…
The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 3, 2025, Perspective Therapeutics, Inc. (the “Company”) entered into amended and restated employment agreements (the “A&R Employment Agreements”) with each of Johan (Thijs) Spoor, the Company’s Chief Executive Officer, Jonathan Hunt, the Company’s Chief Accounting Officer, and Dr. Markus Puhlmann, the Company’s Chief Medical Officer (ea…
Results of Operations and Financial Condition. On October 20, 2025, Perspective Therapeutics, Inc. (the “Company”) issued a press release announcing updated interim results from its Phase 1/2a clinical trial of [ 212 Pb]VMT-α-NET for the treatment and diagnosis of patients with unresectable or metastatic somatostatin receptor subtype 2-expressing neuroendocrine tumors that are being presented at the European Society for Medical Oncology Congress 2025 taking place October 17-21, 2025 in Berlin…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 2, 2025, the Board of Directors (the “Board”) of Perspective Therapeutics, Inc. (the “Company”) appointed Mr. Joel Sendek as the Company’s Chief Financial Officer and principal financial officer, in each case effective as of September 4, 2025 (the “Effective Date”). As of the Effective Date, Mr. Juan Graham ceased serving as the Compan…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 2, 2025, the Board of Directors (the “Board”) of Perspective Therapeutics, Inc. (the “Company”), upon the recommendation of the Nominations and Corporate Governance Committee of the Board (the “Nominations Committee”), voted to increase the size of the Board from five to six directors (the “Director Increase”) and to appoint Maya Marti…
The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after…
The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after…
The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.